What is the prevalence of Adenoid Cystic Carcinoma?

Adenoid cystic carcinoma is a rare malignancy of the secretory glands, with an estimated annual incidence of approximately 3 to 4.5 cases per million people. While exact global prevalence is difficult to determine, it is classified as a rare disease and accounts for about 1% of all head and neck cancers.

How common is Adenoid Cystic Carcinoma?

Adenoid cystic carcinoma is considered a rare disease. Because it often grows slowly and can occur in various secretory glands—including the salivary glands, lacrimal glands, and breasts—it is frequently underdiagnosed or misclassified in early stages. Current data from the NIH GARD and Orphanet suggest that while it is the most common malignant tumor of the minor salivary glands, its overall population prevalence remains low compared to more common carcinomas.

What are the demographic patterns of Adenoid Cystic Carcinoma?

Understanding the epidemiology of adenoid cystic carcinoma involves looking at specific population trends:

• Gender Distribution: Studies indicate a slight female predominance in the incidence of adenoid cystic carcinoma.


• Age of Onset: The condition is predominantly diagnosed in adults, with a peak incidence typically occurring between the ages of 40 and 60.


• Geographic/Ethnic Variation: There is no definitive evidence of significant geographic or ethnic clusters, though global registry data continues to be refined.

Why is accurate prevalence data for Adenoid Cystic Carcinoma challenging?

Obtaining precise statistics for adenoid cystic carcinoma is complicated by its indolent (slow-growing) nature and its ability to arise in diverse anatomical sites. Patients may live for many years with the disease, making "prevalence" (the number of people living with the disease) higher than "incidence" (new cases per year). At DiseaseMaps.org, we have 119 people with adenoid cystic carcinoma who have joined our community, providing a vital real-world perspective that complements clinical registry data.

Next steps

• Consult an oncologist specializing in head and neck cancers or rare salivary gland tumors.


• Connect with the 119 members of the adenoid cystic carcinoma community at DiseaseMaps.org to share experiences.


• Inquire with your medical team about clinical trials specifically targeting the MYB-NFIB gene fusion, which is a hallmark of this condition.

Medical disclaimer: This content is for informational purposes only and does not constitute medical advice, diagnosis, or treatment; always seek the advice of your physician regarding a medical condition.

References

• Orphanet (ORPHA:1376) – Rare disease database for adenoid cystic carcinoma.


• NIH Genetic and Rare Diseases Information Center (GARD) – Fact sheets on salivary gland cancers.


• National Cancer Institute (NCI) – Surveillance, Epidemiology, and End Results (SEER) Program data.


• Adenoid Cystic Carcinoma Research Foundation (ACCRF) – Patient-centered clinical resources.